{"log_id": 1724981084889968246, "direction": 0, "words_result_num": 42, "words_result": [{"probability": {"variance": 0, "average": 0.999853, "min": 0.999606}, "location": {"width": 63, "top": 249, "height": 24, "left": 177}, "words": "乳腺癌"}, {"probability": {"variance": 0.000163, "average": 0.996801, "min": 0.928661}, "location": {"width": 602, "top": 275, "height": 34, "left": 179}, "words": "大量流行病学研究和一项随机安慰剂对照试验,即妇女健康倡议(W"}, {"probability": {"variance": 0, "average": 0.995243, "min": 0.995236}, "location": {"width": 111, "top": 287, "height": 20, "left": 852}, "words": " Health Initiat"}, {"probability": {"variance": 0.00596, "average": 0.986072, "min": 0.486907}, "location": {"width": 829, "top": 303, "height": 36, "left": 178}, "words": "WHI)发现:正在或最近使用HRT疗法的患者,乳腺癌总体风险随HRT治疗年数的延长而增"}, {"probability": {"variance": 0, "average": 0.999617, "min": 0.999617}, "location": {"width": 22, "top": 333, "height": 22, "left": 178}, "words": "加"}, {"probability": {"variance": 0.000233, "average": 0.99541, "min": 0.907706}, "location": {"width": 833, "top": 377, "height": 40, "left": 174}, "words": "对于单一雌激素替代疗法,在重新分析51项流行病学研究(其中>80%的人使用单一雌激素替代"}, {"probability": {"variance": 0.008067, "average": 0.970784, "min": 0.637929}, "location": {"width": 509, "top": 409, "height": 25, "left": 173}, "words": "疗法)和一项流行病学研究,即百万妇女研究( Million W"}, {"probability": {"variance": 0.018733, "average": 0.941904, "min": 0.513618}, "location": {"width": 250, "top": 416, "height": 23, "left": 735}, "words": "Sudy,MwS)的原始资料后"}, {"probability": {"variance": 0.004504, "average": 0.971579, "min": 0.625953}, "location": {"width": 831, "top": 433, "height": 36, "left": 175}, "words": "得出结果相似的使用者乳腺癌相对危险度(RR),分别为1.35(95%CI1.21-1.49)和1.30(95%CI"}, {"probability": {"variance": 0.000585, "average": 0.986709, "min": 0.92827}, "location": {"width": 61, "top": 465, "height": 17, "left": 189}, "words": "21-1.40"}, {"probability": {"variance": 1.1e-05, "average": 0.998044, "min": 0.987042}, "location": {"width": 830, "top": 507, "height": 38, "left": 174}, "words": "对于联合雌激素和孕激素的HRT疗法,已有多个流行病学研究报道称使用者乳腺癌总体风险高"}, {"probability": {"variance": 7e-06, "average": 0.998367, "min": 0.991923}, "location": {"width": 147, "top": 535, "height": 26, "left": 171}, "words": "于单用雌激素者"}, {"probability": {"variance": 0.004054, "average": 0.980282, "min": 0.695354}, "location": {"width": 825, "top": 582, "height": 40, "left": 177}, "words": "ws报道,相对于从未使用HRT疗法者,使用不同种类的雌激素-孕激素联合HRT疗法者的"}, {"probability": {"variance": 0.006838, "average": 0.958893, "min": 0.533695}, "location": {"width": 831, "top": 611, "height": 38, "left": 170}, "words": "乳腺癌风险(RR=2.00,95%CI:1.882.12)都高于单用雌激素(RR=1.30,95%CI:1.21-1.40)或替"}, {"probability": {"variance": 0.003026, "average": 0.976154, "min": 0.76797}, "location": {"width": 340, "top": 639, "height": 27, "left": 171}, "words": "勃龙(RR=1.45;95%CI1.25-1.68)的患者"}, {"probability": {"variance": 0.006392, "average": 0.976312, "min": 0.547155}, "location": {"width": 827, "top": 686, "height": 38, "left": 172}, "words": "WH试验报道,与安慰剂相比,所有使用雌激素-孕激素联合HRT疗法(CEE+MPA)者5.6年"}, {"probability": {"variance": 0.00565, "average": 0.969503, "min": 0.669038}, "location": {"width": 356, "top": 715, "height": 26, "left": 171}, "words": "后乳腺癌的风险为1.24(95%CI1.01-1.54)"}, {"probability": {"variance": 0.009588, "average": 0.963982, "min": 0.54549}, "location": {"width": 476, "top": 764, "height": 28, "left": 170}, "words": "根据MWS和WHl试验所计算出的乳腺癌绝对危险如下"}, {"probability": {"variance": 0.006, "average": 0.970362, "min": 0.723794}, "location": {"width": 449, "top": 813, "height": 27, "left": 172}, "words": "MWS基于发达国家中已知的乳腺癌平均发病率推测"}, {"probability": {"variance": 0.002244, "average": 0.985651, "min": 0.76041}, "location": {"width": 617, "top": 839, "height": 33, "left": 209}, "words": "每1,000名50-64岁从未使用HRT疗法的女性中约有32例被诊断为乳腺癌"}, {"probability": {"variance": 0.003924, "average": 0.980001, "min": 0.70087}, "location": {"width": 653, "top": 865, "height": 34, "left": 208}, "words": "每1,000名正在或最近使用HRT疗法的同龄患者中,新增的乳腺癌病例数为"}, {"probability": {"variance": 6e-06, "average": 0.99846, "min": 0.990696}, "location": {"width": 244, "top": 894, "height": 23, "left": 208}, "words": "单一雌激素替代疗法使用者"}, {"probability": {"variance": 1.8e-05, "average": 0.996227, "min": 0.98822}, "location": {"width": 158, "top": 921, "height": 23, "left": 331}, "words": "03例(最佳估计值"}, {"probability": {"variance": 0.000415, "average": 0.988423, "min": 0.93207}, "location": {"width": 173, "top": 925, "height": 22, "left": 595}, "words": "te=1.5)5年使用期"}, {"probability": {"variance": 0.000417, "average": 0.990705, "min": 0.911362}, "location": {"width": 295, "top": 946, "height": 26, "left": 333}, "words": "-7例(最佳估计值=5)10年使用期"}, {"probability": {"variance": 1.4e-05, "average": 0.998032, "min": 0.984773}, "location": {"width": 325, "top": 971, "height": 28, "left": 207}, "words": "雌激素和孕激素联合替代疗法使用者"}, {"probability": {"variance": 0.000725, "average": 0.990438, "min": 0.881558}, "location": {"width": 286, "top": 999, "height": 25, "left": 327}, "words": "5-7例(最佳估计值=6)5年使用期"}, {"probability": {"variance": 0.001583, "average": 0.98317, "min": 0.840082}, "location": {"width": 325, "top": 1027, "height": 25, "left": 334}, "words": "8-20例(最佳估计值=19)10年使用期"}, {"probability": {"variance": 0.00634, "average": 0.972365, "min": 0.600463}, "location": {"width": 832, "top": 1071, "height": 38, "left": 166}, "words": "WHI试验中随访50-79岁女性5.6年后,因雌激素-孕激素联合HRT(CEE+MPA)疗法导致新增8"}, {"probability": {"variance": 0.001157, "average": 0.986105, "min": 0.85764}, "location": {"width": 265, "top": 1100, "height": 26, "left": 165}, "words": "例浸润性乳腺癌/10,000女性年"}, {"probability": {"variance": 0, "average": 0.999528, "min": 0.99862}, "location": {"width": 288, "top": 1125, "height": 27, "left": 164}, "words": "根据试验资料的计算结果可认为"}, {"probability": {"variance": 7e-06, "average": 0.998482, "min": 0.989575}, "location": {"width": 229, "top": 1154, "height": 22, "left": 203}, "words": "安慰剂组中每1,000名女性"}, {"probability": {"variance": 9e-06, "average": 0.998529, "min": 0.98643}, "location": {"width": 356, "top": 1178, "height": 28, "left": 244}, "words": "5年内将约有16例被诊断为侵袭性乳腺癌"}, {"probability": {"variance": 0.002647, "average": 0.978387, "min": 0.74701}, "location": {"width": 672, "top": 1204, "height": 35, "left": 204}, "words": "雌激素-孕激素联合HRT(CEE+MPA)组中每1,000名女性,新增病例数将为"}, {"probability": {"variance": 0.002079, "average": 0.978008, "min": 0.829738}, "location": {"width": 287, "top": 1234, "height": 24, "left": 243}, "words": "0-9例(最佳估计值=4)5年使用期"}, {"probability": {"variance": 0.003254, "average": 0.987575, "min": 0.628752}, "location": {"width": 746, "top": 1257, "height": 34, "left": 164}, "words": "女性不论在什么年龄(45-65岁之间)开始HRT疗法,她们的乳腺癌新增病例数大致相同"}, {"probability": {"variance": 1e-06, "average": 0.999009, "min": 0.997876}, "location": {"width": 96, "top": 1307, "height": 23, "left": 168}, "words": "子宫内膜癌"}, {"probability": {"variance": 9e-06, "average": 0.99859, "min": 0.980673}, "location": {"width": 830, "top": 1332, "height": 35, "left": 161}, "words": "留有完整子宫的女性患子宫内膜增生过长和子宫内膜癌的风险随使用不加孕激素的雌激素治疗"}, {"probability": {"variance": 0.000228, "average": 0.99656, "min": 0.898228}, "location": {"width": 838, "top": 1356, "height": 42, "left": 160}, "words": "时间的延长而增加。根据流行病学研究的资料,50-65岁不使用HRT疗法的女性,子宫内膜癌"}, {"probability": {"variance": 0.005767, "average": 0.979283, "min": 0.564967}, "location": {"width": 834, "top": 1382, "height": 42, "left": 159}, "words": "最佳风险估计值约为5例1,000人。不加孕激素的雌激素使用者患子宫内膜癌的风险取决于治疗"}, {"probability": {"variance": 0.001002, "average": 0.993315, "min": 0.787907}, "location": {"width": 833, "top": 1409, "height": 39, "left": 160}, "words": "时间和雌激素剂量而比不使用HRT疗法者大2-12倍不等。单一雌激素疗法中添加孕激素后能大"}, {"probability": {"variance": 1e-06, "average": 0.998842, "min": 0.996428}, "location": {"width": 180, "top": 1439, "height": 24, "left": 161}, "words": "大降低所增加的风险"}], "language": 3}